BioXcel Therapeutics is trading 5.04% down at $0.15 after its August 27, 2026 Chapter 11 filing and proposed sale of substantially all assets to Teva.
- Bankruptcy filing pressures equity holders amid uncertain, court-supervised sale proceedings.
- Reuters reported estimated liabilities of $100 million to $500 million versus assets of $10 million to $50 million.
- Teva’s stalking-horse offer includes $57.5 million upfront and contingent milestone payments, subject to court approval; August 31, 2026 after-hours weakness follows a 10.25% regular-session decline.